Prometic Life Sciences Inc.

PLI-T

TSE:PLI

13.60
0.03 (0.22%)
Prometic Life Sciences Inc. is a Canadian publicly traded biopharmaceutical company. Prometic products are used in the purification of biologics, drug development, proteomics and the removal of pathogens.
More at Wikipedia

Analysis and Opinions about PLI-T

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
September 19, 2019
They hit a financing crisis and needed cash. So, they issued 20 billion share at 1.5 cents per share. A massive dilution that destroyed the shareholder base. Avoid.
Show full opinionHide full opinion
They hit a financing crisis and needed cash. So, they issued 20 billion share at 1.5 cents per share. A massive dilution that destroyed the shareholder base. Avoid.
SELL
SELL
April 15, 2019
Technically, the new low at 8 cents does not offer anything meaningful. He would look at tax loss selling. Take the tax loss and move on.
Show full opinionHide full opinion
Technically, the new low at 8 cents does not offer anything meaningful. He would look at tax loss selling. Take the tax loss and move on.
SELL
SELL
April 12, 2019
He has followed this for a long time. It extracts protein from blood plasma and a drug that treats inflammation. They have added massive debt -- about $250 billion. He thinks there will be dramatic issues ahead and it will not end well for common shareholders.
Show full opinionHide full opinion
He has followed this for a long time. It extracts protein from blood plasma and a drug that treats inflammation. They have added massive debt -- about $250 billion. He thinks there will be dramatic issues ahead and it will not end well for common shareholders.
DON'T BUY
DON'T BUY
April 5, 2019
The recent significant fall of 22% last week, would not be a signal to buy. He would stay away.
Show full opinionHide full opinion
The recent significant fall of 22% last week, would not be a signal to buy. He would stay away.
WAIT
WAIT
December 12, 2018
The big challenge is getting their product to market. They have most of the cash they need into 2020, which should buy them enought time. He is watching to see how revenues ramp up next year.
Show full opinionHide full opinion
The big challenge is getting their product to market. They have most of the cash they need into 2020, which should buy them enought time. He is watching to see how revenues ramp up next year.
SELL
SELL
November 15, 2018
He has been disappointed in the company but in clinical trials and the FDA process, things don't go as well as you want. They ran into a cash crush so they extended the terms of their debt. It is way down and the time-frame is extended. You should move on. There is tax loss selling.
Show full opinionHide full opinion
He has been disappointed in the company but in clinical trials and the FDA process, things don't go as well as you want. They ran into a cash crush so they extended the terms of their debt. It is way down and the time-frame is extended. You should move on. There is tax loss selling.
DON'T BUY
DON'T BUY
October 11, 2018

The key is their ability to take a bag of plasma and extract a bunch of proteins. They can sell as much as they can produce. The market is concerned about their spending in R&D. It appears to be a long way away from payday.

Show full opinionHide full opinion

The key is their ability to take a bag of plasma and extract a bunch of proteins. They can sell as much as they can produce. The market is concerned about their spending in R&D. It appears to be a long way away from payday.

DON'T BUY
DON'T BUY
May 15, 2018

They have patents on plasma protein drugs that are interesting. The company had significant success pushing these through the FDA stages but they recently ran into a delay and the stock dropped precipitously. He has been short for a while thinking the market cap was overvalued for the ultimate end market they were pursuing. Now that the stock has dropped so much, his short position is smaller. This is a highly speculative position.

Show full opinionHide full opinion

They have patents on plasma protein drugs that are interesting. The company had significant success pushing these through the FDA stages but they recently ran into a delay and the stock dropped precipitously. He has been short for a while thinking the market cap was overvalued for the ultimate end market they were pursuing. Now that the stock has dropped so much, his short position is smaller. This is a highly speculative position.

SELL
SELL
March 26, 2018

He is short this company presently. The market cap is quite high compared to his estimate of value. The company appears to be quite promotional compared to others. Their plasma protein product is easy to get through the FDA and subject to hype at each easy approval stage. He does not see revenues and earnings to back it up.

Show full opinionHide full opinion

He is short this company presently. The market cap is quite high compared to his estimate of value. The company appears to be quite promotional compared to others. Their plasma protein product is easy to get through the FDA and subject to hype at each easy approval stage. He does not see revenues and earnings to back it up.

WATCH
WATCH
February 28, 2018

He believes this has been very volatile due to an overhang and the potential need for more financing. It is stabilizing now and they have received an investment from the Thompson family. He thinks they should begin to receive approval soon with sales later this year. They do not own it presently, although they have held it in the past.

Show full opinionHide full opinion

He believes this has been very volatile due to an overhang and the potential need for more financing. It is stabilizing now and they have received an investment from the Thompson family. He thinks they should begin to receive approval soon with sales later this year. They do not own it presently, although they have held it in the past.

COMMENT
COMMENT
February 20, 2018

Prometic has two parts to its business. They can buy a bag of plasma for $200US and extract 11-13 high profile proteins. They have already applied to do 4 of those. There is an almost unlimited market for one of those, plasminogen, because there is no other supply of it. They’re also working on another drug that targets fibrosis. The studies for this drug are very costly, so PLI has had to raise a lot of capital. This will take a long time, is very risky, but will pay off well if successful. They are expected to break even next year based on their protein extraction.

Show full opinionHide full opinion

Prometic has two parts to its business. They can buy a bag of plasma for $200US and extract 11-13 high profile proteins. They have already applied to do 4 of those. There is an almost unlimited market for one of those, plasminogen, because there is no other supply of it. They’re also working on another drug that targets fibrosis. The studies for this drug are very costly, so PLI has had to raise a lot of capital. This will take a long time, is very risky, but will pay off well if successful. They are expected to break even next year based on their protein extraction.

COMMENT
COMMENT
January 5, 2018

The near to intermediate term is a bit of a challenge. They have technology to extract proteins from a bag of plasma. Their specialty is that they require a lot less CapX and operating costs to do it, and can end up getting much higher yields. The current process, which is over 40 years old, is maximized and optimized for something totally different in the proteins they were getting. They have approval to get plasminogen. Spending a ton of money to go through the formal drug testing process. It’s not expected to earn any money in 2018, but a loss of $.13 a share. Expected to break even in 2019.

Show full opinionHide full opinion

The near to intermediate term is a bit of a challenge. They have technology to extract proteins from a bag of plasma. Their specialty is that they require a lot less CapX and operating costs to do it, and can end up getting much higher yields. The current process, which is over 40 years old, is maximized and optimized for something totally different in the proteins they were getting. They have approval to get plasminogen. Spending a ton of money to go through the formal drug testing process. It’s not expected to earn any money in 2018, but a loss of $.13 a share. Expected to break even in 2019.

COMMENT
COMMENT
July 14, 2017

Doing interesting drug trials, with a near-term opportunity for their orphan drug Placminogen, a specialty protein. With Placminogen they can basically sell almost everything they can produce. Earnings estimates for 2019 is basically zero. You are buying this for 2 reasons. 1.) The manufacturing process; buying a bag of plasma for $120, breaking out a large number of proteins, and selling it over time for about $1000. 2.) their drug PBI4050 which is targeted towards fibrosis, where early results are quite positive. To develop a drug and go through phase 2 and 3 drug trials, is extremely expensive. If your time frame is 3 years, he thinks you will be happy. A speculative company working with some very interesting drug opportunities.

Show full opinionHide full opinion

Doing interesting drug trials, with a near-term opportunity for their orphan drug Placminogen, a specialty protein. With Placminogen they can basically sell almost everything they can produce. Earnings estimates for 2019 is basically zero. You are buying this for 2 reasons. 1.) The manufacturing process; buying a bag of plasma for $120, breaking out a large number of proteins, and selling it over time for about $1000. 2.) their drug PBI4050 which is targeted towards fibrosis, where early results are quite positive. To develop a drug and go through phase 2 and 3 drug trials, is extremely expensive. If your time frame is 3 years, he thinks you will be happy. A speculative company working with some very interesting drug opportunities.

COMMENT
COMMENT
June 23, 2017

This does blood plasma protein. It is something that has been very easy for them to get FDA approval for their treatments. However, revenues and cash flow just haven’t come as they promised in the past. Did a pretty dilutive equity raise recently, which didn’t go that well. He is Short this, and probably will stay Short until the stock from the equity deal gets cleaned up.

Show full opinionHide full opinion

This does blood plasma protein. It is something that has been very easy for them to get FDA approval for their treatments. However, revenues and cash flow just haven’t come as they promised in the past. Did a pretty dilutive equity raise recently, which didn’t go that well. He is Short this, and probably will stay Short until the stock from the equity deal gets cleaned up.

HOLD
HOLD
June 22, 2017

They are going to have a lot of catalysts between now and Q1 2018 on their drugs and some of their trials. He sold it higher up for technical reasons. He would hold onto it because of the catalysts.

Show full opinionHide full opinion

They are going to have a lot of catalysts between now and Q1 2018 on their drugs and some of their trials. He sold it higher up for technical reasons. He would hold onto it because of the catalysts.

Showing 1 to 15 of 77 entries